Improved Disease-modifying Therapies Through Joint Pharmacophore Mining

Acelot is a life science based R&D company focusing on advanced technology for drug discovery. This technology is employed in-house for a number of drug-discovery projects in the central nervous system area.

jps_screen At the core of Acelot's technology is a novel and unique computer algorithm, "JPS", that has been developed at the University of California and was validated in a variety of studies. JPS allows the identification of latent pharmacophore information and can be used for rapid lead identification and optimization even for drug development projects without clear target information or crystallography data. Furthermore, JPS is useful for screening against undesired pathways and targets to minimize the risk of side-effects. Additional information on the underlying technology can be found here.

drug_pipeline Acelot's JPS-powered drug discovery pipeline comprises several compound families for Alzheimer's and Parkinson's disease. These compounds span a variety of mechanisms-of-action and have been validated in a number of in-vitro assays to date. Acelot is actively looking for potential development partners for any of these compound families. Additional information can be found here.


September 15, 2016
Acelot has been awarded a prestigious SBIR Grant from the National Institutes of Health for the discovery of novel LXR-based leads for Alzheimer's disease based on Acelot's computer-based JPS method.

December 22, 2015
U.S. patent 9,218,460 on the JPS method has been granted with Ambuj Singh as one of the inventors. Acelot holds an exclusive license for this patent.

May 31, 2015
Acelot co-authored an article in Bioorganic & Medicinal Chemistry Letters on the use of its unique JPS technology for the discovery of novel LRRK2 inhibitors for the treatment of Parkinson's disease.